View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsYield10 Bioscience 将来の成長Future 基準チェック /06現在、 Yield10 Bioscienceの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長25.3%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報Price Target Changed • Aug 17Price target decreased by 33% to US$9.83Down from US$14.67, the current price target is an average from 3 analysts. New target price is 2,187% above last closing price of US$0.43. Stock is down 85% over the past year. The company is forecast to post a net loss per share of US$2.01 next year compared to a net loss per share of US$2.76 last year.Price Target Changed • Jan 19Price target increased to US$14.67Up from US$12.75, the current price target is an average from 3 analysts. New target price is 464% above last closing price of US$2.60. Stock is down 32% over the past year. The company is forecast to post a net loss per share of US$2.68 next year compared to a net loss per share of US$2.33 last year.Price Target Changed • Nov 16Price target increased to US$14.67Up from US$12.75, the current price target is an average from 4 analysts. New target price is 449% above last closing price of US$2.67. Stock is down 52% over the past year. The company is forecast to post a net loss per share of US$2.58 next year compared to a net loss per share of US$2.33 last year.Major Estimate Revision • Aug 17Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$620.0k to US$530.0k. EPS estimate increased from -US$2.72 to -US$2.58 per share. Biotechs industry in the US expected to see average net income decline 57% next year. Consensus price target of US$12.25 unchanged from last update. Share price rose 9.1% to US$2.93 over the past week.Major Estimate Revision • May 18Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$970.0k to US$620.0k. EPS estimate increased from -US$2.82 to -US$2.72 per share. Biotechs industry in the US expected to see average net income decline 52% next year. Consensus price target down from US$12.75 to US$12.25. Share price rose 26% to US$2.78 over the past week.Price Target Changed • Apr 27Price target decreased to US$15.33Down from US$21.50, the current price target is an average from 3 analysts. New target price is 367% above last closing price of US$3.28. Stock is down 68% over the past year. The company is forecast to post a net loss per share of US$2.67 next year compared to a net loss per share of US$2.33 last year.すべての更新を表示Recent updatesお知らせ • Dec 08Yield10 Bioscience, Inc. Filed for BankruptcyYield10 Bioscience, Inc., along with its two affiliates, filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the District of Delaware on December 6, 2024. The debtor listed both its assets and liabilities in the range of $1 million to $10 million. The debtor is represented by Frederick Brian Rosner of The Rosner Law Group LLC as its legal counsel.お知らせ • Dec 07Motion for Joint Administration Filed by Yield10 Bioscience, Inc.Yield10 Bioscience, Inc., along with its affiliates, filed a motion for joint administration of their Chapter 11 bankruptcy cases in the US Bankruptcy Court on December 6, 2024. As per the motion, the debtor seeks the joint administration of the cases of its affiliates, Yield10 Bioscience Securities Corp., and Yield10 Oilseeds Inc., with its own case for administrative and procedural purposes. Yield10 Bioscience, Inc. has been proposed as the lead debtor.お知らせ • Nov 13Yield10 Bioscience, Inc. announced that it has received $3 million in fundingOn November 12, 2024, Yield10 Bioscience, Inc. closed the transaction. The company has received $2,500,000 in its second and final tranche. The note along with unpaid accrued interest shall become immediately due and payable.お知らせ • Oct 04Nuseed Nutritional US Inc. entered into an asset purchase agreement to acquire Substantially all assets of Yield10 Bioscience, Inc./Yield10 Oilseeds, Inc. from Yield10 Bioscience, Inc. (OTCPK:YTEN) and Yield10 Oilseeds, Inc. for $5 million.Nuseed Nutritional US Inc. entered into an asset purchase agreement to acquire Substantially all assets of Yield10 Bioscience, Inc. (OTCPK:YTEN)/Yield10 Oilseeds, Inc. for $5 million on October 1, 2024. Pursuant to the transaction, Nuseed Nutritional US Inc. will pay an aggregate purchase price of up to $5,000,000 in cash, which amount will be reduced by amounts owed under the secured promissory note issued by Yield10 Bioscience, Inc. and Yield10 Oilseeds, Inc. to Nuseed Nutritional US Inc. that remain outstanding at closing, and the amount of assumed payables assumed by Nuseed Nutritional US Inc. at closing. As of October 1, 2024, the amounts owed under the promissory note is $1.85 million. The transaction have been unanimously approved by the board of directors of Yield10 Bioscience, Inc. and Yield10 Oilseeds, Inc. and is subject to stockholders approval. A preliminary proxy statement has been filed by Yield10 Bioscience, Inc. and Yield10 Oilseeds, Inc. and will prepare and file a definitive proxy statement with the SEC. Subject to customary exceptions, the Asset Purchase Agreement may be terminated by either party if the closing has not occurred by December 31, 2024. In case of termination of transaction, Yield10 Bioscience, Inc. and Yield10 Oilseeds, Inc. will pay a termination fee of $0.12 million.お知らせ • May 17Yield10 Bioscience, Inc.(OTCPK:YTEN) dropped from NASDAQ Composite IndexYield10 Bioscience, Inc.has been dropped from NASDAQ Composite Index.お知らせ • May 16Yield10 Bioscience Announces Delisting from NasdaqOn May 14, 2024, Yield10 Bioscience, Inc. (the ‘Company’) received notice from The Nasdaq Stock Market LLC (‘Nasdaq’) that the Nasdaq Hearings Panel has determined to delist the Company’s common stock. Suspension of trading in the Company’s common stock will be effective at the open of trading on May 16, 2024. Following the delisting of its common stock from the Nasdaq Capital Market, the Company will continue to be a reporting company under the Securities Exchange Act of 1934. The Company expects its common stock will commence trading on the OTC Markets Group platform at the open of trading on May 16, 2024 under the symbol ‘YTEN.’ The Company plan to apply for trading on the OTC-QB market. The Company has a period of 15 days from the date of the notice letter to submit a written request for a review of the Nasdaq Hearings Panel’s delisting determination by the Nasdaq Listing and Hearing Review Council (the ‘Listing Council’). The Company does not plan to appeal the Nasdaq Hearings Panel’s determination and expects that a Form 25-NSE will be filed with the Securities and Exchange Commission (‘SEC’), which would remove the Company’s common stock from listing and registration on Nasdaq. As previously reported, on May 18, 2023, the Staff of the Nasdaq informed the Company that it did not comply with the minimum stockholders’ equity requirement pursuant to Nasdaq Listing Rule 5550(b)(1) (the ‘Stockholders’ Equity Requirement’). The Staff granted the Company’s request for an extension until September 30, 2023, which was subsequently extended until November 14, 2023, to comply with Rule 5550(b)(1). On November 15, 2023, the company received a notice from Nasdaq of the Staff’s determination that the Company had not met the terms of such extension. The Company requested an appeal of the Staff’s determination and submitted a hearing request to the Panel, which request stayed any delisting action by the Staff until the hearing process was concluded. Yield10 participated in a hearing before the Panel on February 6, 2024, and on February 13, 2024, the company was notified by the Panel that the Company had been granted an additional extension to remain listed on The Nasdaq Capital Market until May 13, 2024, subject to certain conditions. These conditions included that the Company provide a written update on the status of its plans to obtain financing and strengthen its balance sheet by March 15, 2024, as well as provide prompt notification of any significant events that may occur during the period of extension that may affect the Company’s compliance with Nasdaq requirements. The company provided the Panel with the requested update on March 14, 2024. The Company was granted an additional period, or until May 13, 2024, to regain compliance with the Rule.お知らせ • May 04Yield10 Bioscience Announces 1-for-24 Reverse Stock Split to Increase the Market Price Per Share of the its Common Stock to Maintain the Listing of its Common Stock on The Nasdaq Capital MarketYield10 Bioscience, Inc. (‘Yield10’ or the ‘Company’) announced that it will effect a 1-for-24 reverse stock split of its common stock, following stockholder approval of the reverse stock split at its special stockholder meeting held on April 26, 2024. The 1-for-24 reverse stock split will be effective as of 5:00 p.m. Eastern Time, after the close of trading on the Nasdaq Capital Market, on May 2, 2024, and the Company's common stock will begin trading on a split-adjusted basis on May 3, 2024. The reverse stock split will reduce the number of shares of the Company’s common stock currently outstanding from 15,420,951 shares to 642,539 shares. The number of authorized shares of the Company's common stock will remain 60 million shares. The reverse stock split is intended to increase the market price per share of the Company’s common stock to allow the Company to maintain the listing of its common stock on The Nasdaq Capital Market. The Company's common stock will continue to trade on The Nasdaq Capital Market under the symbol ‘YTEN.’ The new CUSIP number for the common stock following the reverse stock split will be 98585K854.お知らせ • May 01Yield10 Bioscience, Inc., Annual General Meeting, Jun 07, 2024Yield10 Bioscience, Inc., Annual General Meeting, Jun 07, 2024, at 10:00 US Eastern Standard Time. Agenda: To elect two Class III directors to board of directors for three-year terms; to approve an amendment to amended and restated certificate of incorporation, as amended to increase the number of authorized shares of common stock from 60,000,000 to 150,000,000; to approve a proposal to adjourn the Annual Meeting to a later date or dates, if necessary, or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the amendment to the Current Charter to increase the number of authorized shares of common stock; to ratify the appointment of Berkowitz Pollack Brant Advisors + CPAs, LLP as independent registered public accounting firm for fiscal year ended December 31, 2023 and the fiscal year ending December 31, 2024; and to consider other matters.お知らせ • Mar 30Yield10 Bioscience Receives Written Notice from The Nasdaq Stock Market LLC Regarding Not Eligible for Second 180 Day Compliance Period for the Minimum Bid Price Rule DeficiencyAs previously reported, Yield10 Bioscience, Inc. (the ‘Company’) received a letter from the staff (the ‘Staff’) of The Nasdaq Stock Market LLC (‘Nasdaq’) on September 25, 2023, stating that for the previous 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the ‘Minimum Bid Price Rule’). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an initial period of 180 calendar days, or until March 25, 2024, to regain compliance with the Minimum Bid Price Rule. The Company was unable to regain compliance with the Minimum Bid Price Rule prior to the expiration of the 180 calendar day period. Also as previously reported, the Company participated in a hearing before the Nasdaq Hearings Panel (the ‘Panel’) on February 6, 2024. On February 13, 2024, the Company was notified by the Panel that it had been granted an additional extension to remain listed on The Nasdaq Capital Market until May 13, 2024, subject to certain conditions. These conditions include that the Company provide a written update on the status of its plans to obtain financing and strengthen its balance sheet by March 15, 2024, as well as provide prompt notification of any significant events during the period of extension that may affect the Company's compliance with Nasdaq requirements. The Company provided this update to Nasdaq on March 14, 2024. On March 26, 2024, the Company received written notice (the ‘Notice’) from the Staff stating that the Company is not eligible for a second 180 day compliance period for the Minimum Bid Price Rule deficiency because the Company does not comply with the $5,000,000 minimum stockholders’ equity initial listing requirement for The Nasdaq Capital Market. The Notice indicates that the Company must present its views with respect to this deficiency to the Panel in writing no later than April 2, 2024, which it intends to do. Among other measures, the Company intends to schedule a special meeting of its shareholders for April 26, 2024 to approve a reverse stock split, in order to increase the price of its common stock to a level that will satisfy the Minimum Bid Price Rule. There continues to be no immediate effect on the listing of the Company’s common stock, which continues to trade on The Nasdaq Capital Market under the symbol ‘YTEN’. The Company is working diligently to satisfy, and intends to regain compliance with, the Minimum Bid Price Rule. However, there can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Rule or that Nasdaq will grant the Company a further extension of time to achieve compliance with the Minimum Bid Price Rule. The Company intends to continue to monitor its closing bid price for its common stock and will continue considering all available options to comply with the Minimum Bid Price Rule as may be necessary.お知らせ • Mar 29Yield10 Bioscience, Inc. to Report Q4, 2023 Results on Apr 01, 2024Yield10 Bioscience, Inc. announced that they will report Q4, 2023 results on Apr 01, 2024お知らせ • Mar 26Yield10 Bioscience, Inc. Announces the Plant Biosafety Office of the Canadian Food Inspection Agency Clear Genome-edited E3902 Camelina for Planting in CanadaYield10 Bioscience, Inc. reported that the Plant Biosafety Office (PBO) of the Canadian Food Inspection Agency (CFIA) recently reviewed information on the company's E3902 Camelina sativa (Camelina) and determined that E3902 is not a Plant with Novel Trait (PNT) and is not subject to a pre-market notification under Part V of the Seeds Regulations. The company's E3902 Camelina combines genome edits in three proprietary genetic traits, C3008a, C3008b and C3009, that result in an increase in oil production by 5% and produce a lighter seed coat color as compared to the parental Camelina line. E3902 Camelina remains subject to other applicable requirements of the Seeds Act and Regulations in Canada.お知らせ • Feb 17Nasdaq Hearings Panel Grants Yield10 Bioscience, Inc. an Additional Extension to Remain Listed on the Nasdaq Capital Market Until May 13, 2024As previously disclosed, Yield10 Bioscience, Inc. ("Yield10" or the "Company") requested an appeal of the Nasdaq Listing Qualifications Department's ("Staff") determination that the Company had not satisfied the terms of an extension that the Company had been granted to meet Nasdaq listing requirements relating to minimum stockholders' equity. Yield10 participated in a hearing before the Nasdaq Hearings Panel ("Panel") on February 6, 2024. On February 13, 2024, the Company was notified by the Panel that it had been granted an additional extension to remain listed on The Nasdaq Capital Market until May 13, 2024, subject to certain conditions. These conditions include that the Company provide a written update on the status of its plans to obtain financing and strengthen its balance sheet by March 15, 2024, as well as provide prompt notification of any significant events that may occur during the period of extension that may affect the Company's compliance with Nasdaq requirements. Also as previously disclosed, on September 25, 2023, Yield10 received a deficiency letter from the Staff notifying the Company that it was not in compliance with the requirement to maintain a minimum bid price of at least $1.00 per share pursuant to Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until March 25, 2024, to regain compliance with this listing requirement. To regain compliance, the closing bid price of the Company's common stock must be $1.00 per share or more for a minimum of 10 consecutive business days at any time before March 25, 2024. If the Company does not regain compliance with Rule 5550(a)(2) by March 25, 2024, the Company may be eligible for an additional 180 calendar day compliance period. The Company continues to work diligently to regain compliance with all applicable Nasdaq listing criteria; however, there can be no assurance that the Company will be able to satisfy the continued listing criteria during the extension period relating to the stockholders' equity requirement that ends on May 13, 2024.お知らせ • Feb 08Yield10 Bioscience, Inc. Provides an Update on Its Omega-3 Camelina ProgramYield10 Bioscience, Inc. provided an update on its Omega-3 Camelina program. The Company has taken the strategic decision to prioritize in 2024 the execution of activities intended to accelerate and advance the Omega-3 Camelina program toward commercialization. Yield10 also reported that it has completed contra season production in Chile of Omega-3 EPA8 Camelina, which produces the eicosapentaenoic acid (“EPA”) component of the omega-3 oil found in fish. The EPA8 Camelina variety is intended to produce EPA oil for the significant market opportunity in aquafeed and human nutrition. In 2024, subject to the availability of sufficient financial resources, Yield10 plans to continue to execute seed scale-up of EPA8 Camelina to enable production of the Company’s first commercial omega-3 product for use in aquafeed. The Company is also transferring the EPA trait into proprietary Yield10 herbicide tolerant Camelina germplasm to boost in-field agronomics and yield. To enable planting of Omega-3 Camelina without restrictions in the US as well as to de-regulate oil and meal, Yield10 is progressing the execution of a regulatory program involving U.S. Department of Agriculture Animal & Plant Health Inspection Service (“USDA-APHIS”), the U.S. Environmental Protection Agency (“U.S. EPA”), and the U.S. Food and Drug Administration (“FDA”). In the fall of 2023, the Company contracted 50 acres of contra season production of the EPA8 Camelina in Chile. The crop was recently harvested, and the cleaned seed is in inventory for future use. Yield10 is currently investigating options for seed crushing to extract oil and the pilot scale production of aquafeed formulations.お知らせ • Jan 08Yield10 Bioscience, Inc. Files Request for Regulatory Status Review with USDA-APHIS for Camelina Designed to Produce the EPA and DHA Components of Omega-3 OilYield10 Bioscience, Inc. announced that the company recently filed a request for a Regulatory Status Review (RSR) with USDA-APHIS Biotechnology Regulatory Services (“BRS”) under the Sustainable, Ecological, Consistent, Uniform, Responsible, Efficient (SECURE) Rule for proprietary elite Camelina sativa (Camelina) varieties designed to produce seed oil containing both essential omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). The genetic pathway deployed in the omega-3 Camelina DHA1 line described in the Company’s RSR submission produces oil containing approximately 10% EPA and 10% DHA, closely resembling the omega-3 EPA/DHA fatty acid profile of northern hemisphere fish oil. Yield10 is making plans to conduct field work with omega-3 (EPA+DHA) Camelina with the goal to begin the ramp-up of seed inventory for future planting as well as to produce omega-3 oil for use in business development activities. Currently, the primary source of the essential fatty acids EPA and DHA is ocean-caught fish, where omega-3 oil produced from anchovy harvest is the industry benchmark. Producing omega-3 fatty acids in Camelina represents a potential way to enable a reliable supply of high-quality omega-3 oils to meet the global demand for EPA and DHA. In 2020, Yield10 signed an exclusive collaboration agreement with Rothamsted to support Rothamsted’s Flagship Program to develop omega-3 oils in Camelina. As part of the collaboration agreement, the Company received an exclusive option to sign a global, exclusive license agreement for the technology. Yield10 recently announced it had exercised this option and plans to finalize [1] the global exclusive license with Rothamsted. Yield10 prioritized development and scale-up of EPA omega-3 Camelina and filed an RSR [2] for approval of this line for production in the United States with USDA-APHIS in 2023. Yield10 planted omega-3 (EPA) Camelina at acre-scale in Chile during the fourth quarter of 2023 to begin the ramp-up of seed inventory for future planting, as well as to produce omega-3 (EPA) oil samples for business development activities. Following immediately behind the EPA Camelina, Yield10 is scaling up an omega-3 Camelina line to produce oil containing both EPA and DHA fatty acids. This line has been extensively tested by Rothamsted and published aquafeed studies have shown that the EPA + DHA oil produced in Camelina has the potential to serve as a drop-in replacement for fish oil. Furthermore, published human clinical studies have shown this oil to be an effective alternative to fish oil in the human diet. The SECURE Rule was published on May 18, 2020 and represents the first comprehensive revision of APHIS’ biotechnology regulations since 1987. The revisions enable APHIS to regulate organisms developed using genetic engineering for plant pest risk with greater precision and reduces the regulatory burden for developers of organisms that are unlikely to pose plant pest risks. Once a specific plant developed through genetic engineering is found not to require regulation, new varieties of the plant containing the same genetic modification would similarly not be regulated. Camelina plants containing omega-3 traits are subject to regulation by the U.S. Food and Drug Administration.お知らせ • Nov 18Yield10 Bioscience Receives Non-Compliance Notice From NasdaqAs previously disclosed, on May 18, 2023, the Nasdaq Listing Qualifications Department (the “Staff”), informed Yield10 Bioscience, Inc. (the “Company”) that it did not comply with the minimum stockholders’ equity requirement of at least $2,500,000 pursuant to Nasdaq Listing Rule 5550(b)(1) (“Rule 5550(b)(1)”). The Staff granted the Company’s request for an extension until September 30, 2023, which was subsequently extended until November 14, 2023, to comply with Rule 5550(b)(1). On November 15, 2023, the Company received a notice from Nasdaq of the Staff’s determination that the Company had not met the terms of such extension. Specifically, the Company did not complete a capital raising transaction of up to $12,000,000, and the Company has not yet finalized a definitive investment and offtake agreement for low-carbon intensity Camelina feedstock oil with Marathon Petroleum Corporation ("Marathon") or converted an outstanding $1,000,000 note issued to Marathon into the Company's common stock. The Company has requested an appeal of the Staff’s determination and submitted a hearing request to the Nasdaq Hearings Panel (the “Panel”), which request stays any delisting action by the Staff until the hearing process has concluded. As previously disclosed, on September 25, 2023, the Company also received a deficiency letter from the Staff notifying the Company that it was not in compliance with the requirement to maintain a minimum bid price of at least $1.00 per share pursuant to Nasdaq Listing Rule 5550(a)(2). The Company is diligently working to regain compliance with all applicable Nasdaq listing criteria; however, there can be no assurance that a hearing with the Panel will be successful or, if the Panel determines to continue the Company’s listing, that the Company will be able to satisfy the continued listing criteria subsequent to the hearing.お知らせ • Nov 15Yield10 Bioscience, Inc. Contemplates Bankruptcy. Yield10 Bioscience, Inc. is contemplating filing for bankruptcy, as of November 14, 2023. According to company’s SEC filing, the company anticipate that their present capital resources will not be sufficient to fund its planned operations beyond early December 2023, which raises substantial doubt as to the Company's ability to continue as a going concern. It has recorded losses since its initial founding except in 2012. The Company had an accumulated deficit of $410,886. As of September 30, 2023, it had restricted cash of $264, consisting of $229 held in connection with the lease agreement.お知らせ • Nov 09Yield10 Bioscience, Inc. to Report Q3, 2023 Results on Nov 14, 2023Yield10 Bioscience, Inc. announced that they will report Q3, 2023 results on Nov 14, 2023お知らせ • Oct 12Yield10 Bioscience, Inc. Provides Update on Recent Advancements in the Development of Elite Herbicide Tolerant CamelinaYield10 Bioscience, Inc. announced recent advancements toward enabling weed control for Camelina cultivation and supporting grower adoption of the crop for production of low-carbon intensity feedstock oil for the biofuel market. Control of broadleaf weeds is essential for the rapid adoption and success of commercial crops in North America. Yield10 is establishing a leadership position in the development of herbicide tolerant (“HT”) Camelina to drive broad acceptance of the crop by growers. The Company is developing Camelina with tolerance to a broad leaf herbicide, which has been used safely in commercial crop production for over 25 years. In addition, Yield10 is developing an herbicide package for Camelina, incorporating tolerance to over-the-top application of broadleaf herbicide as well as tolerance to soil residual Group 2 herbicides, which are commonly used to control weeds in cereal crops. Development of commercial quality herbicide tolerant Camelina. Broad-spectrum herbicides have been used to protect seed yield by controlling broadleaf weeds. Yield10 has demonstrated tolerance to over-the-top spray application of a commonly used broad leaf herbicide in its E3902 HT Camelina in three cycles of field testing. Additional field test data is being collected and grain and protein meal samples analyzed to support the use of HT Camelina meal in livestock feed. Throughout 2023, Yield10 has conducted seed scale-up activities that will continue in the contra season in Chile. Yield10 is building seed inventory for a planned commercial launch of HT spring Camelina as early as 2025. Last year, Yield10 filed a request for Regulatory Status Review (“RSR”) with USDA-APHIS Biotechnology Regulatory Services (“BRS”) for Yield10’s broadleaf HT Camelina under the Sustainable, Ecological, Consistent, Uniform, Responsible, Efficient (“SECURE”) Rule. A response from the agency is pending. Earlier this year, one of the manufacturers of the herbicide submitted a label amendment to the Environmental Protection Agency to allow use of their broadleaf herbicide on Camelina. Development of commercial quality stacked HT Camelina. Yield10 is developing elite Camelina varieties with a robust weed control package based on tolerance to a broad leaf herbicide application as well as to soil residues of Group 2 herbicides (“IMI”/imidazolinones and “SU”/sulfonylurea). Yield10 recently announced it demonstrated tolerance to over-the-top spray application of the commonly used broad leaf herbicide as well as tolerance to Group 2 herbicide in its spring E3902 stacked HT Camelina. Yield10 plans to conduct seed scale-up activities in contra season in Chile for this variety. Yield10 researchers have developed candidate stacked HT winter Camelina. Yield10 is testing stacked HT winter Camelina in field tests for the first time this winter. Earlier this year Yield10 filed an RSR with USDA-APHIS (BRS) for Yield10’s stacked HT Camelina under the SECURE Rule. A response from the agency is pending. The SECURE Rule was published on May 18, 2020 and represents the first comprehensive revision of APHIS’ biotechnology regulations since 1987. The revisions enable APHIS to regulate organisms developed using genetic engineering for plant pest risk with greater precision and reduce regulatory burden for developers of organisms that are unlikely to pose plant pest risks. Once a specific plant developed through genetic engineering is found not to require regulation, new varieties of the plant containing the same genetic modification would similarly not be regulated. Camelina plants containing herbicide resistance traits are subject to labeling under EPA regulations.お知らせ • Sep 26Yield10 Bioscience, Inc. Receives Non-Compliance Notice from NasdaqOn September 25, 2023, Yield10 Bioscience, Inc. (the “Company”) received a letter from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) providing notification that, for the previous 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until March 25, 2024, to regain compliance. To regain compliance, the closing bid price of the Company’s common stock must be $1.00 per share or more for a minimum of 10 consecutive business days at any time before March 25, 2024. This notice has no immediate effect on the listing of the Company's common stock, which continues to trade on The Nasdaq Capital Market. If the Company regains compliance, Nasdaq will provide the Company with written confirmation and will close the matter. If the Company does not regain compliance with Rule 5550(a)(2) by March 25, 2024, the Company may be eligible for an additional 180 calendar day compliance period. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and would need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. However, if it appears to the Staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq would notify the Company that its securities would be subject to delisting. In the event of such a notification, the Company may appeal the Staff’s determination to delist its securities, but there can be no assurance the Staff would grant the Company’s request for continued listing. The Company intends to monitor the bid price of its common stock and its minimum market value of listed securities and will consider options available to it to achieve compliance.お知らせ • Aug 17Yield10 Bioscience, Inc. has completed a Composite Units Offering in the amount of $3.7375 million.Yield10 Bioscience, Inc. has completed a Composite Units Offering in the amount of $3.7375 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 5,750,000 Price\Range: $0.65 Discount Per Security: $0.0455Price Target Changed • Aug 17Price target decreased by 33% to US$9.83Down from US$14.67, the current price target is an average from 3 analysts. New target price is 2,187% above last closing price of US$0.43. Stock is down 85% over the past year. The company is forecast to post a net loss per share of US$2.01 next year compared to a net loss per share of US$2.76 last year.Reported Earnings • Aug 16Second quarter 2023 earnings released: US$0.64 loss per share (vs US$0.70 loss in 2Q 2022)Second quarter 2023 results: US$0.64 loss per share. Net loss: US$3.68m (loss widened 6.9% from 2Q 2022). Revenue is forecast to grow 61% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in the US.New Risk • Aug 13New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 141% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$11m free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Shareholders have been substantially diluted in the past year (141% increase in shares outstanding). Revenue is less than US$1m (US$361k revenue). Market cap is less than US$10m (US$5.33m market cap). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$13m net loss in 3 years).お知らせ • Aug 12Yield10 Bioscience, Inc. to Report Q2, 2023 Results on Aug 14, 2023Yield10 Bioscience, Inc. announced that they will report Q2, 2023 results on Aug 14, 2023New Risk • Aug 09New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.88m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$11m free cash flow). Revenue is less than US$1m (US$361k revenue). Market cap is less than US$10m (US$9.88m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$13m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (24% increase in shares outstanding).お知らせ • Aug 03Yield10 Bioscience, Inc. Announces Positive Results in the First Field Test of Stacked Herbicide Tolerance Traits in CamelinaYield10 Bioscience, Inc. announced positive results in the first field test of stacked herbicide tolerance ("HT") traits in Camelina. These proprietary stacked HT Camelina varieties developed by Yield10 demonstrate tolerance to the application of an over-the-top herbicide for weed control as well as tolerance to Group 2 herbicide soil residues. These results represent a key advancement for supporting grower adoption of stacked HT Camelina for the biofuel feedstock market by enabling weed control and increased access to acreage previously treated with Group 2 herbicides. Yield10 is executing a program to develop and commercialize spring and winter Camelina varieties with stacked herbicide traits to achieve large acreage adoption of the crop in North America. In the second quarter of 2023, Yield10 researchers initiated the first field tests of candidate E3902 spring Camelina lines deployed with stacked HT traits intended to provide the plants with tolerance to the application of a over-the-top broadleaf herbicide for weed control as Well as tolerance to soil residues of Group 2 herbicides, specifically including tolerance to both imidazolinones ("IMI") and sulfonylureas ("SU"). In the second quarter of 20 23, Yield10 filed a request for Regulatory Status Review (RSR) with USDA-APHIS Biotechnology Regulatory Services (BRS) for stacked herbicide tolerant Camelina under the SECURE Rule, and a response from the agency is pending.New Risk • Aug 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$11m free cash flow). Revenue is less than US$1m (US$361k revenue). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$13m net loss in 3 years). Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (US$13.8m market cap).お知らせ • Jul 27Yield10 Bioscience Files Request for Regulatory Status Review Under Usda-Aphis’S Secure Rule Covering Elite Camelina Designed to Produce the EPA Component of Omega-3 OilYield10 Bioscience, Inc. announced that the Company recently filed a request for a Regulatory Status Review with USDA-APHIS Biotechnology Regulatory Services (BRS) under the SECURE Rule for proprietary elite Camelina varieties containing genes enabling the plant to produce the eicosapentaenoic acid component of omega-3 oil. In spring 2023, Yield10 planted omega-3 (EPA) Camelina at acre-scale in the U.S. to begin the ramp up of seed inventory for future planting as well as to produce oil for use in business development activities. In late 2020, Yield10 signed a collaboration agreement with UK-based Rothamsted Research to support the development of omega-3 oils in Camelina. In addition, Yield10 signed an exclusive option to sign a global, exclusive or non-exclusive license agreement to the Rothamsted omega-3 technology. Yield10 has prioritized the deployment of the EPA component of omega-3 in Camelina as the initial oil profile for commercialization. Yield10 also plans to produce the EPA component of omega-3 co-deployed in Camelina with its advanced technology for a robust trait package including herbicide tolerance. The Company plans to follow this with the development of advanced EPA plus docosahexaenoic acid (“DHA”) producing Camelina varieties. EPA is a polyunsaturated fat (PUFA) that is primarily supplied in the human diet by the consumption of oily fish such as salmon, anchovies, and mackerel. Fish obtain EPA through the consumption of algae. Clinical studies have shown that EPA is beneficial to humans as it lowers triglycerides and reduces low-density lipoprotein (LDL cholesterol) in the blood with beneficial cardiovascular effects. Using Camelina to produce EPA may represent a way to produce this beneficial ingredient without relying on the harvest of ocean fish. Several commercial products containing EPA fatty acids are available on the market including pharmaceuticals, nutritional supplements, and animal feed. The SECURE Rule was published on May 18, 2020 and represents the first comprehensive revision of APHIS’ biotechnology regulations since 1987. The revisions enable APHIS to regulate organisms developed using genetic engineering for plant pest risk with greater precision and reduces the regulatory burden for developers of organisms that are unlikely to pose plant pest risks. Once a specific plant developed through genetic engineering is found not to require regulation, new varieties of the plant containing the same genetic modification would similarly not be regulated. Camelina plants containing omega-3 traits are subject to regulation by the U.S. Food and Drug Administration.お知らせ • May 22Yield10 Bioscience Receives A Deficiency Letter from Nasdaq Regarding Minimum Stockholders' Equity Requirement for Continued Listing on the Nasdaq Capital MarketOn May 18, 2023, Yield10 Bioscience, Inc. (the Company") received a deficiency letter (the Letter") from the Listing Qualifications Department (the Staff") of the Nasdaq Stock Market (Nasdaq") notifying the Company thatit is not in compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on the Nasdaq Capital Market tomaintain stockholders' equity of at least $2,500,000 (the Stockholders' Equity Requirement"). The Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, filed with the Securities and ExchangeCommission on May 12, 2023, reported stockholders' equity of $1,143,000, which is below the Stockholders' Equity Requirement for continued listing on the Nasdaq Capital Market. As of the date of this Current Report on Form8-K, the Company does not have a market value of listed securities of $35 million, or net income from continued operations of $500,000 in the most recently completed fiscal year or in two of the last three most recentlycompleted fiscal years, the alternative quantitative standards for continued listing on the Nasdaq Capital Market. The Letter has no immediate effect on the Company's continued listing on the Nasdaq Capital Market, subject to the Company's compliance with the other continued listing requirements. In accordance with Nasdaq rules, the Company has been provided 45 calendar days, or until July 3, 2023, to submit a plan to regain compliance (theCompliance Plan"). If the Compliance Plan is acceptable to the Staff, they may grant an extension of 180 calendar days from the date of the Staff notification to regain compliance with the Stockholders' EquityRequirement. If the Staff does not accept the Compliance Plan, the Staff will provide written notification to the Company that the Compliance Plan has been rejected. At that time, the Company may appeal the Staff's determination to a Nasdaq Hearings Panel. The Company intends to submit the Compliance Plan on or before July 3, 2023, monitor its stockholders' equity and, if appropriate, consider further available options to regain compliance with the Stockholders' Equity Requirement. There can be no assurance that the Company will be able to regain compliance with the Rule.Reported Earnings • May 11First quarter 2023 earnings: EPS and revenues miss analyst expectationsFirst quarter 2023 results: US$0.76 loss per share (further deteriorated from US$0.68 loss in 1Q 2022). Net loss: US$3.78m (loss widened 14% from 1Q 2022). Revenue missed analyst estimates by 18%. Earnings per share (EPS) also missed analyst estimates by 20%. Revenue is forecast to grow 64% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 75% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.Recent Insider Transactions • May 11Insider recently bought US$1m worth of stockOn the 5th of May, Jack Schuler bought around 336k shares on-market at roughly US$2.98 per share. This transaction amounted to 53% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$402k more in shares than they have sold in the last 12 months.お知らせ • May 05Yield10 Bioscience, Inc. to Report Q1, 2023 Results on May 10, 2023Yield10 Bioscience, Inc. announced that they will report Q1, 2023 results on May 10, 2023Reported Earnings • Mar 16Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: US$2.76 loss per share (further deteriorated from US$2.33 loss in FY 2021). Net loss: US$13.6m (loss widened 23% from FY 2021). Revenue missed analyst estimates by 7.8%. Earnings per share (EPS) also missed analyst estimates by 3.0%. Revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 97% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.Price Target Changed • Jan 19Price target increased to US$14.67Up from US$12.75, the current price target is an average from 3 analysts. New target price is 464% above last closing price of US$2.60. Stock is down 32% over the past year. The company is forecast to post a net loss per share of US$2.68 next year compared to a net loss per share of US$2.33 last year.Reported Earnings • Nov 17Third quarter 2022 earnings: EPS and revenues miss analyst expectationsThird quarter 2022 results: US$0.71 loss per share (further deteriorated from US$0.49 loss in 3Q 2021). Net loss: US$3.49m (loss widened 46% from 3Q 2021). Revenue missed analyst estimates by 17%. Earnings per share (EPS) also missed analyst estimates by 7.2%. Revenue is forecast to grow 68% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 97% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.Price Target Changed • Nov 16Price target increased to US$14.67Up from US$12.75, the current price target is an average from 4 analysts. New target price is 449% above last closing price of US$2.67. Stock is down 52% over the past year. The company is forecast to post a net loss per share of US$2.58 next year compared to a net loss per share of US$2.33 last year.Major Estimate Revision • Aug 17Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$620.0k to US$530.0k. EPS estimate increased from -US$2.72 to -US$2.58 per share. Biotechs industry in the US expected to see average net income decline 57% next year. Consensus price target of US$12.25 unchanged from last update. Share price rose 9.1% to US$2.93 over the past week.Reported Earnings • Aug 11Second quarter 2022 earnings: EPS and revenues miss analyst expectationsSecond quarter 2022 results: US$0.70 loss per share (down from US$0.64 loss in 2Q 2021). Net loss: US$3.44m (loss widened 11% from 2Q 2021). Revenue missed analyst estimates by 35%. Earnings per share (EPS) also missed analyst estimates by 1.4%. Over the next year, revenue is forecast to grow 310%, compared to a 52% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 94% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings.Seeking Alpha • Aug 10Yield10 Bioscience GAAP EPS of $0.70 beats by $1.39, revenue of $0.1M misses by $0.06MYield10 Bioscience press release (NASDAQ:YTEN): Q2 GAAP EPS of $0.70 beats by $1.39. Revenue of $0.1M (-41.2% Y/Y) misses by $0.06M.Major Estimate Revision • May 18Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$970.0k to US$620.0k. EPS estimate increased from -US$2.82 to -US$2.72 per share. Biotechs industry in the US expected to see average net income decline 52% next year. Consensus price target down from US$12.75 to US$12.25. Share price rose 26% to US$2.78 over the past week.Reported Earnings • May 13First quarter 2022 earnings: EPS and revenues miss analyst expectationsFirst quarter 2022 results: US$0.68 loss per share (down from US$0.60 loss in 1Q 2021). Net loss: US$3.33m (loss widened 30% from 1Q 2021). Revenue missed analyst estimates by 14%. Earnings per share (EPS) also missed analyst estimates by 4.2%. Over the next year, revenue is forecast to grow 481%, compared to a 25% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings.Price Target Changed • Apr 27Price target decreased to US$15.33Down from US$21.50, the current price target is an average from 3 analysts. New target price is 367% above last closing price of US$3.28. Stock is down 68% over the past year. The company is forecast to post a net loss per share of US$2.67 next year compared to a net loss per share of US$2.33 last year.Price Target Changed • Mar 11Price target decreased to US$17.00Down from US$24.50, the current price target is an average from 2 analysts. New target price is 215% above last closing price of US$5.40. Stock is down 60% over the past year. The company is forecast to post a net loss per share of US$2.50 next year compared to a net loss per share of US$2.33 last year.分析記事 • Nov 12Is Yield10 Bioscience (NASDAQ:YTEN) In A Good Position To Invest In Growth?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Reported Earnings • Nov 12Third quarter 2021 earnings released: US$0.49 loss per share (vs US$0.87 loss in 3Q 2020)Third quarter 2021 results: Net loss: US$2.40m (loss widened 11% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 78% per year but the company’s share price has fallen by 53% per year, which means it is significantly lagging earnings.Major Estimate Revision • Aug 18Consensus revenue estimates fall to US$890.0kThe consensus outlook for revenues in 2021 has deteriorated. 2021 revenue forecast decreased from US$1.08m to US$890.0k. Forecast losses increased from -US$2.23 to -US$2.58 per share. Biotechs industry in the US expected to see average net income decline 21% next year. Consensus price target down from US$24.50 to US$21.50. Share price fell 18% to US$5.84 over the past week.Price Target Changed • Aug 13Price target decreased to US$21.50Down from US$24.50, the current price target is an average from 2 analysts. New target price is 225% above last closing price of US$6.61. Stock is up 22% over the past year.Reported Earnings • Aug 13Second quarter 2021 earnings released: US$0.64 loss per share (vs US$0.92 loss in 2Q 2020)Second quarter 2021 results: Net loss: US$3.09m (loss widened 72% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 74% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings.分析記事 • Jul 19Yield10 Bioscience (NASDAQ:YTEN) Is In A Good Position To Deliver On Growth PlansWe can readily understand why investors are attracted to unprofitable companies. For example, although...分析記事 • May 18Yield10 Bioscience, Inc.'s (NASDAQ:YTEN) CEO Will Probably Find It Hard To See A Huge Raise This YearThe underwhelming share price performance of Yield10 Bioscience, Inc. ( NASDAQ:YTEN ) in the past three years would...Major Estimate Revision • May 18Consensus revenue estimates fall to US$1.08mThe consensus outlook for revenues in 2021 has deteriorated. 2021 revenue forecast decreased from US$1.41m to US$1.08m. Forecast losses increased from -US$2.06 to -US$2.23 per share. Biotechs industry in the US expected to see average net income decline 8.7% next year. Consensus price target of US$24.50 unchanged from last update. Share price fell 22% to US$7.50 over the past week.Reported Earnings • May 14First quarter 2021 earnings released: US$0.60 loss per share (vs US$2.12 loss in 1Q 2020)First quarter 2021 results: Net loss: US$2.56m (loss narrowed 29% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 74% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings.分析記事 • Apr 14Here's Why We're Watching Yield10 Bioscience's (NASDAQ:YTEN) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, Yield10 Bioscience...Major Estimate Revision • Mar 23Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast fell from US$1.47m to US$1.29m. EPS estimate increased from -US$2.32 to -US$2.06 per share. Biotechs industry in the US expected to see average net income growth of 4.2% next year. Consensus price target of US$25.33 unchanged from last update. Share price fell 3.1% to US$15.56 over the past week.Reported Earnings • Mar 20Full year 2020 earnings released: US$4.30 loss per share (vs US$35.50 loss in FY 2019)Full year 2020 results: Net loss: US$10.2m (loss narrowed 21% from FY 2019). Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Feb 09New 90-day high: US$18.86The company is up 213% from its price of US$6.03 on 10 November 2020. The American market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 25% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$27.40 per share.分析記事 • Jan 22When Will Yield10 Bioscience, Inc. (NASDAQ:YTEN) Become Profitable?We feel now is a pretty good time to analyse Yield10 Bioscience, Inc.'s ( NASDAQ:YTEN ) business as it appears the... このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Yield10 Bioscience は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:YTEN.Q - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/20241-13-6-6N/A3/31/20240-13-8-8N/A12/31/20230-14-10-10N/A9/30/20230-14-11-11N/A6/30/20230-14-12-12N/A3/31/20230-14-11-11N/A12/31/20220-14-12-11N/A9/30/20221-13-11-11N/A6/30/20220-12-10-10N/A3/31/20221-12-10-10N/A12/31/20211-11-9-9N/A9/30/20211-11-9-9N/A6/30/20211-10-9-9N/A3/31/20211-9-9-9N/A12/31/20201-10-9-9N/A9/30/20201-14-10-10N/A6/30/20201-14-9-9N/A3/31/20201-14-9-9N/A12/31/20191-13-9-9N/A9/30/20191-8-7-7N/A6/30/20191-9-8-8N/A3/31/20191-9-8-8N/A12/31/20181-9-9-9N/A9/30/20181-11-9-9N/A6/30/20181-11-9-9N/A3/31/20181-11N/A-9N/A12/31/20171-11N/A-8N/A9/30/20171-8N/A-9N/A6/30/20171-8N/A-11N/A3/31/20171-8N/A-10N/A12/31/20161-9N/A-14N/A9/30/20161-11N/A-17N/A6/30/20160-7N/A-17N/A3/31/20161-10N/A-22N/A12/31/20151-12N/A-22N/A9/30/20152-15N/A-22N/A6/30/20153-24N/A-23N/A3/31/20153-25N/A-22N/A12/31/20143-27N/A-25N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: YTEN.Qの予測収益成長が 貯蓄率 ( 3.3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: YTEN.Qの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: YTEN.Qの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: YTEN.Qの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: YTEN.Qの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: YTEN.Qの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/12/11 02:35終値2025/12/03 00:00収益2024/06/30年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Yield10 Bioscience, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。11 アナリスト機関Han JangAegis Capital CorporationPamela BassettCantor Fitzgerald & Co.Amit DayalH.C. Wainwright & Co.8 その他のアナリストを表示
Price Target Changed • Aug 17Price target decreased by 33% to US$9.83Down from US$14.67, the current price target is an average from 3 analysts. New target price is 2,187% above last closing price of US$0.43. Stock is down 85% over the past year. The company is forecast to post a net loss per share of US$2.01 next year compared to a net loss per share of US$2.76 last year.
Price Target Changed • Jan 19Price target increased to US$14.67Up from US$12.75, the current price target is an average from 3 analysts. New target price is 464% above last closing price of US$2.60. Stock is down 32% over the past year. The company is forecast to post a net loss per share of US$2.68 next year compared to a net loss per share of US$2.33 last year.
Price Target Changed • Nov 16Price target increased to US$14.67Up from US$12.75, the current price target is an average from 4 analysts. New target price is 449% above last closing price of US$2.67. Stock is down 52% over the past year. The company is forecast to post a net loss per share of US$2.58 next year compared to a net loss per share of US$2.33 last year.
Major Estimate Revision • Aug 17Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$620.0k to US$530.0k. EPS estimate increased from -US$2.72 to -US$2.58 per share. Biotechs industry in the US expected to see average net income decline 57% next year. Consensus price target of US$12.25 unchanged from last update. Share price rose 9.1% to US$2.93 over the past week.
Major Estimate Revision • May 18Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$970.0k to US$620.0k. EPS estimate increased from -US$2.82 to -US$2.72 per share. Biotechs industry in the US expected to see average net income decline 52% next year. Consensus price target down from US$12.75 to US$12.25. Share price rose 26% to US$2.78 over the past week.
Price Target Changed • Apr 27Price target decreased to US$15.33Down from US$21.50, the current price target is an average from 3 analysts. New target price is 367% above last closing price of US$3.28. Stock is down 68% over the past year. The company is forecast to post a net loss per share of US$2.67 next year compared to a net loss per share of US$2.33 last year.
お知らせ • Dec 08Yield10 Bioscience, Inc. Filed for BankruptcyYield10 Bioscience, Inc., along with its two affiliates, filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the District of Delaware on December 6, 2024. The debtor listed both its assets and liabilities in the range of $1 million to $10 million. The debtor is represented by Frederick Brian Rosner of The Rosner Law Group LLC as its legal counsel.
お知らせ • Dec 07Motion for Joint Administration Filed by Yield10 Bioscience, Inc.Yield10 Bioscience, Inc., along with its affiliates, filed a motion for joint administration of their Chapter 11 bankruptcy cases in the US Bankruptcy Court on December 6, 2024. As per the motion, the debtor seeks the joint administration of the cases of its affiliates, Yield10 Bioscience Securities Corp., and Yield10 Oilseeds Inc., with its own case for administrative and procedural purposes. Yield10 Bioscience, Inc. has been proposed as the lead debtor.
お知らせ • Nov 13Yield10 Bioscience, Inc. announced that it has received $3 million in fundingOn November 12, 2024, Yield10 Bioscience, Inc. closed the transaction. The company has received $2,500,000 in its second and final tranche. The note along with unpaid accrued interest shall become immediately due and payable.
お知らせ • Oct 04Nuseed Nutritional US Inc. entered into an asset purchase agreement to acquire Substantially all assets of Yield10 Bioscience, Inc./Yield10 Oilseeds, Inc. from Yield10 Bioscience, Inc. (OTCPK:YTEN) and Yield10 Oilseeds, Inc. for $5 million.Nuseed Nutritional US Inc. entered into an asset purchase agreement to acquire Substantially all assets of Yield10 Bioscience, Inc. (OTCPK:YTEN)/Yield10 Oilseeds, Inc. for $5 million on October 1, 2024. Pursuant to the transaction, Nuseed Nutritional US Inc. will pay an aggregate purchase price of up to $5,000,000 in cash, which amount will be reduced by amounts owed under the secured promissory note issued by Yield10 Bioscience, Inc. and Yield10 Oilseeds, Inc. to Nuseed Nutritional US Inc. that remain outstanding at closing, and the amount of assumed payables assumed by Nuseed Nutritional US Inc. at closing. As of October 1, 2024, the amounts owed under the promissory note is $1.85 million. The transaction have been unanimously approved by the board of directors of Yield10 Bioscience, Inc. and Yield10 Oilseeds, Inc. and is subject to stockholders approval. A preliminary proxy statement has been filed by Yield10 Bioscience, Inc. and Yield10 Oilseeds, Inc. and will prepare and file a definitive proxy statement with the SEC. Subject to customary exceptions, the Asset Purchase Agreement may be terminated by either party if the closing has not occurred by December 31, 2024. In case of termination of transaction, Yield10 Bioscience, Inc. and Yield10 Oilseeds, Inc. will pay a termination fee of $0.12 million.
お知らせ • May 17Yield10 Bioscience, Inc.(OTCPK:YTEN) dropped from NASDAQ Composite IndexYield10 Bioscience, Inc.has been dropped from NASDAQ Composite Index.
お知らせ • May 16Yield10 Bioscience Announces Delisting from NasdaqOn May 14, 2024, Yield10 Bioscience, Inc. (the ‘Company’) received notice from The Nasdaq Stock Market LLC (‘Nasdaq’) that the Nasdaq Hearings Panel has determined to delist the Company’s common stock. Suspension of trading in the Company’s common stock will be effective at the open of trading on May 16, 2024. Following the delisting of its common stock from the Nasdaq Capital Market, the Company will continue to be a reporting company under the Securities Exchange Act of 1934. The Company expects its common stock will commence trading on the OTC Markets Group platform at the open of trading on May 16, 2024 under the symbol ‘YTEN.’ The Company plan to apply for trading on the OTC-QB market. The Company has a period of 15 days from the date of the notice letter to submit a written request for a review of the Nasdaq Hearings Panel’s delisting determination by the Nasdaq Listing and Hearing Review Council (the ‘Listing Council’). The Company does not plan to appeal the Nasdaq Hearings Panel’s determination and expects that a Form 25-NSE will be filed with the Securities and Exchange Commission (‘SEC’), which would remove the Company’s common stock from listing and registration on Nasdaq. As previously reported, on May 18, 2023, the Staff of the Nasdaq informed the Company that it did not comply with the minimum stockholders’ equity requirement pursuant to Nasdaq Listing Rule 5550(b)(1) (the ‘Stockholders’ Equity Requirement’). The Staff granted the Company’s request for an extension until September 30, 2023, which was subsequently extended until November 14, 2023, to comply with Rule 5550(b)(1). On November 15, 2023, the company received a notice from Nasdaq of the Staff’s determination that the Company had not met the terms of such extension. The Company requested an appeal of the Staff’s determination and submitted a hearing request to the Panel, which request stayed any delisting action by the Staff until the hearing process was concluded. Yield10 participated in a hearing before the Panel on February 6, 2024, and on February 13, 2024, the company was notified by the Panel that the Company had been granted an additional extension to remain listed on The Nasdaq Capital Market until May 13, 2024, subject to certain conditions. These conditions included that the Company provide a written update on the status of its plans to obtain financing and strengthen its balance sheet by March 15, 2024, as well as provide prompt notification of any significant events that may occur during the period of extension that may affect the Company’s compliance with Nasdaq requirements. The company provided the Panel with the requested update on March 14, 2024. The Company was granted an additional period, or until May 13, 2024, to regain compliance with the Rule.
お知らせ • May 04Yield10 Bioscience Announces 1-for-24 Reverse Stock Split to Increase the Market Price Per Share of the its Common Stock to Maintain the Listing of its Common Stock on The Nasdaq Capital MarketYield10 Bioscience, Inc. (‘Yield10’ or the ‘Company’) announced that it will effect a 1-for-24 reverse stock split of its common stock, following stockholder approval of the reverse stock split at its special stockholder meeting held on April 26, 2024. The 1-for-24 reverse stock split will be effective as of 5:00 p.m. Eastern Time, after the close of trading on the Nasdaq Capital Market, on May 2, 2024, and the Company's common stock will begin trading on a split-adjusted basis on May 3, 2024. The reverse stock split will reduce the number of shares of the Company’s common stock currently outstanding from 15,420,951 shares to 642,539 shares. The number of authorized shares of the Company's common stock will remain 60 million shares. The reverse stock split is intended to increase the market price per share of the Company’s common stock to allow the Company to maintain the listing of its common stock on The Nasdaq Capital Market. The Company's common stock will continue to trade on The Nasdaq Capital Market under the symbol ‘YTEN.’ The new CUSIP number for the common stock following the reverse stock split will be 98585K854.
お知らせ • May 01Yield10 Bioscience, Inc., Annual General Meeting, Jun 07, 2024Yield10 Bioscience, Inc., Annual General Meeting, Jun 07, 2024, at 10:00 US Eastern Standard Time. Agenda: To elect two Class III directors to board of directors for three-year terms; to approve an amendment to amended and restated certificate of incorporation, as amended to increase the number of authorized shares of common stock from 60,000,000 to 150,000,000; to approve a proposal to adjourn the Annual Meeting to a later date or dates, if necessary, or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the amendment to the Current Charter to increase the number of authorized shares of common stock; to ratify the appointment of Berkowitz Pollack Brant Advisors + CPAs, LLP as independent registered public accounting firm for fiscal year ended December 31, 2023 and the fiscal year ending December 31, 2024; and to consider other matters.
お知らせ • Mar 30Yield10 Bioscience Receives Written Notice from The Nasdaq Stock Market LLC Regarding Not Eligible for Second 180 Day Compliance Period for the Minimum Bid Price Rule DeficiencyAs previously reported, Yield10 Bioscience, Inc. (the ‘Company’) received a letter from the staff (the ‘Staff’) of The Nasdaq Stock Market LLC (‘Nasdaq’) on September 25, 2023, stating that for the previous 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the ‘Minimum Bid Price Rule’). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an initial period of 180 calendar days, or until March 25, 2024, to regain compliance with the Minimum Bid Price Rule. The Company was unable to regain compliance with the Minimum Bid Price Rule prior to the expiration of the 180 calendar day period. Also as previously reported, the Company participated in a hearing before the Nasdaq Hearings Panel (the ‘Panel’) on February 6, 2024. On February 13, 2024, the Company was notified by the Panel that it had been granted an additional extension to remain listed on The Nasdaq Capital Market until May 13, 2024, subject to certain conditions. These conditions include that the Company provide a written update on the status of its plans to obtain financing and strengthen its balance sheet by March 15, 2024, as well as provide prompt notification of any significant events during the period of extension that may affect the Company's compliance with Nasdaq requirements. The Company provided this update to Nasdaq on March 14, 2024. On March 26, 2024, the Company received written notice (the ‘Notice’) from the Staff stating that the Company is not eligible for a second 180 day compliance period for the Minimum Bid Price Rule deficiency because the Company does not comply with the $5,000,000 minimum stockholders’ equity initial listing requirement for The Nasdaq Capital Market. The Notice indicates that the Company must present its views with respect to this deficiency to the Panel in writing no later than April 2, 2024, which it intends to do. Among other measures, the Company intends to schedule a special meeting of its shareholders for April 26, 2024 to approve a reverse stock split, in order to increase the price of its common stock to a level that will satisfy the Minimum Bid Price Rule. There continues to be no immediate effect on the listing of the Company’s common stock, which continues to trade on The Nasdaq Capital Market under the symbol ‘YTEN’. The Company is working diligently to satisfy, and intends to regain compliance with, the Minimum Bid Price Rule. However, there can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Rule or that Nasdaq will grant the Company a further extension of time to achieve compliance with the Minimum Bid Price Rule. The Company intends to continue to monitor its closing bid price for its common stock and will continue considering all available options to comply with the Minimum Bid Price Rule as may be necessary.
お知らせ • Mar 29Yield10 Bioscience, Inc. to Report Q4, 2023 Results on Apr 01, 2024Yield10 Bioscience, Inc. announced that they will report Q4, 2023 results on Apr 01, 2024
お知らせ • Mar 26Yield10 Bioscience, Inc. Announces the Plant Biosafety Office of the Canadian Food Inspection Agency Clear Genome-edited E3902 Camelina for Planting in CanadaYield10 Bioscience, Inc. reported that the Plant Biosafety Office (PBO) of the Canadian Food Inspection Agency (CFIA) recently reviewed information on the company's E3902 Camelina sativa (Camelina) and determined that E3902 is not a Plant with Novel Trait (PNT) and is not subject to a pre-market notification under Part V of the Seeds Regulations. The company's E3902 Camelina combines genome edits in three proprietary genetic traits, C3008a, C3008b and C3009, that result in an increase in oil production by 5% and produce a lighter seed coat color as compared to the parental Camelina line. E3902 Camelina remains subject to other applicable requirements of the Seeds Act and Regulations in Canada.
お知らせ • Feb 17Nasdaq Hearings Panel Grants Yield10 Bioscience, Inc. an Additional Extension to Remain Listed on the Nasdaq Capital Market Until May 13, 2024As previously disclosed, Yield10 Bioscience, Inc. ("Yield10" or the "Company") requested an appeal of the Nasdaq Listing Qualifications Department's ("Staff") determination that the Company had not satisfied the terms of an extension that the Company had been granted to meet Nasdaq listing requirements relating to minimum stockholders' equity. Yield10 participated in a hearing before the Nasdaq Hearings Panel ("Panel") on February 6, 2024. On February 13, 2024, the Company was notified by the Panel that it had been granted an additional extension to remain listed on The Nasdaq Capital Market until May 13, 2024, subject to certain conditions. These conditions include that the Company provide a written update on the status of its plans to obtain financing and strengthen its balance sheet by March 15, 2024, as well as provide prompt notification of any significant events that may occur during the period of extension that may affect the Company's compliance with Nasdaq requirements. Also as previously disclosed, on September 25, 2023, Yield10 received a deficiency letter from the Staff notifying the Company that it was not in compliance with the requirement to maintain a minimum bid price of at least $1.00 per share pursuant to Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until March 25, 2024, to regain compliance with this listing requirement. To regain compliance, the closing bid price of the Company's common stock must be $1.00 per share or more for a minimum of 10 consecutive business days at any time before March 25, 2024. If the Company does not regain compliance with Rule 5550(a)(2) by March 25, 2024, the Company may be eligible for an additional 180 calendar day compliance period. The Company continues to work diligently to regain compliance with all applicable Nasdaq listing criteria; however, there can be no assurance that the Company will be able to satisfy the continued listing criteria during the extension period relating to the stockholders' equity requirement that ends on May 13, 2024.
お知らせ • Feb 08Yield10 Bioscience, Inc. Provides an Update on Its Omega-3 Camelina ProgramYield10 Bioscience, Inc. provided an update on its Omega-3 Camelina program. The Company has taken the strategic decision to prioritize in 2024 the execution of activities intended to accelerate and advance the Omega-3 Camelina program toward commercialization. Yield10 also reported that it has completed contra season production in Chile of Omega-3 EPA8 Camelina, which produces the eicosapentaenoic acid (“EPA”) component of the omega-3 oil found in fish. The EPA8 Camelina variety is intended to produce EPA oil for the significant market opportunity in aquafeed and human nutrition. In 2024, subject to the availability of sufficient financial resources, Yield10 plans to continue to execute seed scale-up of EPA8 Camelina to enable production of the Company’s first commercial omega-3 product for use in aquafeed. The Company is also transferring the EPA trait into proprietary Yield10 herbicide tolerant Camelina germplasm to boost in-field agronomics and yield. To enable planting of Omega-3 Camelina without restrictions in the US as well as to de-regulate oil and meal, Yield10 is progressing the execution of a regulatory program involving U.S. Department of Agriculture Animal & Plant Health Inspection Service (“USDA-APHIS”), the U.S. Environmental Protection Agency (“U.S. EPA”), and the U.S. Food and Drug Administration (“FDA”). In the fall of 2023, the Company contracted 50 acres of contra season production of the EPA8 Camelina in Chile. The crop was recently harvested, and the cleaned seed is in inventory for future use. Yield10 is currently investigating options for seed crushing to extract oil and the pilot scale production of aquafeed formulations.
お知らせ • Jan 08Yield10 Bioscience, Inc. Files Request for Regulatory Status Review with USDA-APHIS for Camelina Designed to Produce the EPA and DHA Components of Omega-3 OilYield10 Bioscience, Inc. announced that the company recently filed a request for a Regulatory Status Review (RSR) with USDA-APHIS Biotechnology Regulatory Services (“BRS”) under the Sustainable, Ecological, Consistent, Uniform, Responsible, Efficient (SECURE) Rule for proprietary elite Camelina sativa (Camelina) varieties designed to produce seed oil containing both essential omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). The genetic pathway deployed in the omega-3 Camelina DHA1 line described in the Company’s RSR submission produces oil containing approximately 10% EPA and 10% DHA, closely resembling the omega-3 EPA/DHA fatty acid profile of northern hemisphere fish oil. Yield10 is making plans to conduct field work with omega-3 (EPA+DHA) Camelina with the goal to begin the ramp-up of seed inventory for future planting as well as to produce omega-3 oil for use in business development activities. Currently, the primary source of the essential fatty acids EPA and DHA is ocean-caught fish, where omega-3 oil produced from anchovy harvest is the industry benchmark. Producing omega-3 fatty acids in Camelina represents a potential way to enable a reliable supply of high-quality omega-3 oils to meet the global demand for EPA and DHA. In 2020, Yield10 signed an exclusive collaboration agreement with Rothamsted to support Rothamsted’s Flagship Program to develop omega-3 oils in Camelina. As part of the collaboration agreement, the Company received an exclusive option to sign a global, exclusive license agreement for the technology. Yield10 recently announced it had exercised this option and plans to finalize [1] the global exclusive license with Rothamsted. Yield10 prioritized development and scale-up of EPA omega-3 Camelina and filed an RSR [2] for approval of this line for production in the United States with USDA-APHIS in 2023. Yield10 planted omega-3 (EPA) Camelina at acre-scale in Chile during the fourth quarter of 2023 to begin the ramp-up of seed inventory for future planting, as well as to produce omega-3 (EPA) oil samples for business development activities. Following immediately behind the EPA Camelina, Yield10 is scaling up an omega-3 Camelina line to produce oil containing both EPA and DHA fatty acids. This line has been extensively tested by Rothamsted and published aquafeed studies have shown that the EPA + DHA oil produced in Camelina has the potential to serve as a drop-in replacement for fish oil. Furthermore, published human clinical studies have shown this oil to be an effective alternative to fish oil in the human diet. The SECURE Rule was published on May 18, 2020 and represents the first comprehensive revision of APHIS’ biotechnology regulations since 1987. The revisions enable APHIS to regulate organisms developed using genetic engineering for plant pest risk with greater precision and reduces the regulatory burden for developers of organisms that are unlikely to pose plant pest risks. Once a specific plant developed through genetic engineering is found not to require regulation, new varieties of the plant containing the same genetic modification would similarly not be regulated. Camelina plants containing omega-3 traits are subject to regulation by the U.S. Food and Drug Administration.
お知らせ • Nov 18Yield10 Bioscience Receives Non-Compliance Notice From NasdaqAs previously disclosed, on May 18, 2023, the Nasdaq Listing Qualifications Department (the “Staff”), informed Yield10 Bioscience, Inc. (the “Company”) that it did not comply with the minimum stockholders’ equity requirement of at least $2,500,000 pursuant to Nasdaq Listing Rule 5550(b)(1) (“Rule 5550(b)(1)”). The Staff granted the Company’s request for an extension until September 30, 2023, which was subsequently extended until November 14, 2023, to comply with Rule 5550(b)(1). On November 15, 2023, the Company received a notice from Nasdaq of the Staff’s determination that the Company had not met the terms of such extension. Specifically, the Company did not complete a capital raising transaction of up to $12,000,000, and the Company has not yet finalized a definitive investment and offtake agreement for low-carbon intensity Camelina feedstock oil with Marathon Petroleum Corporation ("Marathon") or converted an outstanding $1,000,000 note issued to Marathon into the Company's common stock. The Company has requested an appeal of the Staff’s determination and submitted a hearing request to the Nasdaq Hearings Panel (the “Panel”), which request stays any delisting action by the Staff until the hearing process has concluded. As previously disclosed, on September 25, 2023, the Company also received a deficiency letter from the Staff notifying the Company that it was not in compliance with the requirement to maintain a minimum bid price of at least $1.00 per share pursuant to Nasdaq Listing Rule 5550(a)(2). The Company is diligently working to regain compliance with all applicable Nasdaq listing criteria; however, there can be no assurance that a hearing with the Panel will be successful or, if the Panel determines to continue the Company’s listing, that the Company will be able to satisfy the continued listing criteria subsequent to the hearing.
お知らせ • Nov 15Yield10 Bioscience, Inc. Contemplates Bankruptcy. Yield10 Bioscience, Inc. is contemplating filing for bankruptcy, as of November 14, 2023. According to company’s SEC filing, the company anticipate that their present capital resources will not be sufficient to fund its planned operations beyond early December 2023, which raises substantial doubt as to the Company's ability to continue as a going concern. It has recorded losses since its initial founding except in 2012. The Company had an accumulated deficit of $410,886. As of September 30, 2023, it had restricted cash of $264, consisting of $229 held in connection with the lease agreement.
お知らせ • Nov 09Yield10 Bioscience, Inc. to Report Q3, 2023 Results on Nov 14, 2023Yield10 Bioscience, Inc. announced that they will report Q3, 2023 results on Nov 14, 2023
お知らせ • Oct 12Yield10 Bioscience, Inc. Provides Update on Recent Advancements in the Development of Elite Herbicide Tolerant CamelinaYield10 Bioscience, Inc. announced recent advancements toward enabling weed control for Camelina cultivation and supporting grower adoption of the crop for production of low-carbon intensity feedstock oil for the biofuel market. Control of broadleaf weeds is essential for the rapid adoption and success of commercial crops in North America. Yield10 is establishing a leadership position in the development of herbicide tolerant (“HT”) Camelina to drive broad acceptance of the crop by growers. The Company is developing Camelina with tolerance to a broad leaf herbicide, which has been used safely in commercial crop production for over 25 years. In addition, Yield10 is developing an herbicide package for Camelina, incorporating tolerance to over-the-top application of broadleaf herbicide as well as tolerance to soil residual Group 2 herbicides, which are commonly used to control weeds in cereal crops. Development of commercial quality herbicide tolerant Camelina. Broad-spectrum herbicides have been used to protect seed yield by controlling broadleaf weeds. Yield10 has demonstrated tolerance to over-the-top spray application of a commonly used broad leaf herbicide in its E3902 HT Camelina in three cycles of field testing. Additional field test data is being collected and grain and protein meal samples analyzed to support the use of HT Camelina meal in livestock feed. Throughout 2023, Yield10 has conducted seed scale-up activities that will continue in the contra season in Chile. Yield10 is building seed inventory for a planned commercial launch of HT spring Camelina as early as 2025. Last year, Yield10 filed a request for Regulatory Status Review (“RSR”) with USDA-APHIS Biotechnology Regulatory Services (“BRS”) for Yield10’s broadleaf HT Camelina under the Sustainable, Ecological, Consistent, Uniform, Responsible, Efficient (“SECURE”) Rule. A response from the agency is pending. Earlier this year, one of the manufacturers of the herbicide submitted a label amendment to the Environmental Protection Agency to allow use of their broadleaf herbicide on Camelina. Development of commercial quality stacked HT Camelina. Yield10 is developing elite Camelina varieties with a robust weed control package based on tolerance to a broad leaf herbicide application as well as to soil residues of Group 2 herbicides (“IMI”/imidazolinones and “SU”/sulfonylurea). Yield10 recently announced it demonstrated tolerance to over-the-top spray application of the commonly used broad leaf herbicide as well as tolerance to Group 2 herbicide in its spring E3902 stacked HT Camelina. Yield10 plans to conduct seed scale-up activities in contra season in Chile for this variety. Yield10 researchers have developed candidate stacked HT winter Camelina. Yield10 is testing stacked HT winter Camelina in field tests for the first time this winter. Earlier this year Yield10 filed an RSR with USDA-APHIS (BRS) for Yield10’s stacked HT Camelina under the SECURE Rule. A response from the agency is pending. The SECURE Rule was published on May 18, 2020 and represents the first comprehensive revision of APHIS’ biotechnology regulations since 1987. The revisions enable APHIS to regulate organisms developed using genetic engineering for plant pest risk with greater precision and reduce regulatory burden for developers of organisms that are unlikely to pose plant pest risks. Once a specific plant developed through genetic engineering is found not to require regulation, new varieties of the plant containing the same genetic modification would similarly not be regulated. Camelina plants containing herbicide resistance traits are subject to labeling under EPA regulations.
お知らせ • Sep 26Yield10 Bioscience, Inc. Receives Non-Compliance Notice from NasdaqOn September 25, 2023, Yield10 Bioscience, Inc. (the “Company”) received a letter from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) providing notification that, for the previous 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until March 25, 2024, to regain compliance. To regain compliance, the closing bid price of the Company’s common stock must be $1.00 per share or more for a minimum of 10 consecutive business days at any time before March 25, 2024. This notice has no immediate effect on the listing of the Company's common stock, which continues to trade on The Nasdaq Capital Market. If the Company regains compliance, Nasdaq will provide the Company with written confirmation and will close the matter. If the Company does not regain compliance with Rule 5550(a)(2) by March 25, 2024, the Company may be eligible for an additional 180 calendar day compliance period. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and would need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. However, if it appears to the Staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq would notify the Company that its securities would be subject to delisting. In the event of such a notification, the Company may appeal the Staff’s determination to delist its securities, but there can be no assurance the Staff would grant the Company’s request for continued listing. The Company intends to monitor the bid price of its common stock and its minimum market value of listed securities and will consider options available to it to achieve compliance.
お知らせ • Aug 17Yield10 Bioscience, Inc. has completed a Composite Units Offering in the amount of $3.7375 million.Yield10 Bioscience, Inc. has completed a Composite Units Offering in the amount of $3.7375 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 5,750,000 Price\Range: $0.65 Discount Per Security: $0.0455
Price Target Changed • Aug 17Price target decreased by 33% to US$9.83Down from US$14.67, the current price target is an average from 3 analysts. New target price is 2,187% above last closing price of US$0.43. Stock is down 85% over the past year. The company is forecast to post a net loss per share of US$2.01 next year compared to a net loss per share of US$2.76 last year.
Reported Earnings • Aug 16Second quarter 2023 earnings released: US$0.64 loss per share (vs US$0.70 loss in 2Q 2022)Second quarter 2023 results: US$0.64 loss per share. Net loss: US$3.68m (loss widened 6.9% from 2Q 2022). Revenue is forecast to grow 61% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in the US.
New Risk • Aug 13New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 141% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$11m free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Shareholders have been substantially diluted in the past year (141% increase in shares outstanding). Revenue is less than US$1m (US$361k revenue). Market cap is less than US$10m (US$5.33m market cap). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$13m net loss in 3 years).
お知らせ • Aug 12Yield10 Bioscience, Inc. to Report Q2, 2023 Results on Aug 14, 2023Yield10 Bioscience, Inc. announced that they will report Q2, 2023 results on Aug 14, 2023
New Risk • Aug 09New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.88m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$11m free cash flow). Revenue is less than US$1m (US$361k revenue). Market cap is less than US$10m (US$9.88m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$13m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (24% increase in shares outstanding).
お知らせ • Aug 03Yield10 Bioscience, Inc. Announces Positive Results in the First Field Test of Stacked Herbicide Tolerance Traits in CamelinaYield10 Bioscience, Inc. announced positive results in the first field test of stacked herbicide tolerance ("HT") traits in Camelina. These proprietary stacked HT Camelina varieties developed by Yield10 demonstrate tolerance to the application of an over-the-top herbicide for weed control as well as tolerance to Group 2 herbicide soil residues. These results represent a key advancement for supporting grower adoption of stacked HT Camelina for the biofuel feedstock market by enabling weed control and increased access to acreage previously treated with Group 2 herbicides. Yield10 is executing a program to develop and commercialize spring and winter Camelina varieties with stacked herbicide traits to achieve large acreage adoption of the crop in North America. In the second quarter of 2023, Yield10 researchers initiated the first field tests of candidate E3902 spring Camelina lines deployed with stacked HT traits intended to provide the plants with tolerance to the application of a over-the-top broadleaf herbicide for weed control as Well as tolerance to soil residues of Group 2 herbicides, specifically including tolerance to both imidazolinones ("IMI") and sulfonylureas ("SU"). In the second quarter of 20 23, Yield10 filed a request for Regulatory Status Review (RSR) with USDA-APHIS Biotechnology Regulatory Services (BRS) for stacked herbicide tolerant Camelina under the SECURE Rule, and a response from the agency is pending.
New Risk • Aug 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$11m free cash flow). Revenue is less than US$1m (US$361k revenue). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$13m net loss in 3 years). Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (US$13.8m market cap).
お知らせ • Jul 27Yield10 Bioscience Files Request for Regulatory Status Review Under Usda-Aphis’S Secure Rule Covering Elite Camelina Designed to Produce the EPA Component of Omega-3 OilYield10 Bioscience, Inc. announced that the Company recently filed a request for a Regulatory Status Review with USDA-APHIS Biotechnology Regulatory Services (BRS) under the SECURE Rule for proprietary elite Camelina varieties containing genes enabling the plant to produce the eicosapentaenoic acid component of omega-3 oil. In spring 2023, Yield10 planted omega-3 (EPA) Camelina at acre-scale in the U.S. to begin the ramp up of seed inventory for future planting as well as to produce oil for use in business development activities. In late 2020, Yield10 signed a collaboration agreement with UK-based Rothamsted Research to support the development of omega-3 oils in Camelina. In addition, Yield10 signed an exclusive option to sign a global, exclusive or non-exclusive license agreement to the Rothamsted omega-3 technology. Yield10 has prioritized the deployment of the EPA component of omega-3 in Camelina as the initial oil profile for commercialization. Yield10 also plans to produce the EPA component of omega-3 co-deployed in Camelina with its advanced technology for a robust trait package including herbicide tolerance. The Company plans to follow this with the development of advanced EPA plus docosahexaenoic acid (“DHA”) producing Camelina varieties. EPA is a polyunsaturated fat (PUFA) that is primarily supplied in the human diet by the consumption of oily fish such as salmon, anchovies, and mackerel. Fish obtain EPA through the consumption of algae. Clinical studies have shown that EPA is beneficial to humans as it lowers triglycerides and reduces low-density lipoprotein (LDL cholesterol) in the blood with beneficial cardiovascular effects. Using Camelina to produce EPA may represent a way to produce this beneficial ingredient without relying on the harvest of ocean fish. Several commercial products containing EPA fatty acids are available on the market including pharmaceuticals, nutritional supplements, and animal feed. The SECURE Rule was published on May 18, 2020 and represents the first comprehensive revision of APHIS’ biotechnology regulations since 1987. The revisions enable APHIS to regulate organisms developed using genetic engineering for plant pest risk with greater precision and reduces the regulatory burden for developers of organisms that are unlikely to pose plant pest risks. Once a specific plant developed through genetic engineering is found not to require regulation, new varieties of the plant containing the same genetic modification would similarly not be regulated. Camelina plants containing omega-3 traits are subject to regulation by the U.S. Food and Drug Administration.
お知らせ • May 22Yield10 Bioscience Receives A Deficiency Letter from Nasdaq Regarding Minimum Stockholders' Equity Requirement for Continued Listing on the Nasdaq Capital MarketOn May 18, 2023, Yield10 Bioscience, Inc. (the Company") received a deficiency letter (the Letter") from the Listing Qualifications Department (the Staff") of the Nasdaq Stock Market (Nasdaq") notifying the Company thatit is not in compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on the Nasdaq Capital Market tomaintain stockholders' equity of at least $2,500,000 (the Stockholders' Equity Requirement"). The Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, filed with the Securities and ExchangeCommission on May 12, 2023, reported stockholders' equity of $1,143,000, which is below the Stockholders' Equity Requirement for continued listing on the Nasdaq Capital Market. As of the date of this Current Report on Form8-K, the Company does not have a market value of listed securities of $35 million, or net income from continued operations of $500,000 in the most recently completed fiscal year or in two of the last three most recentlycompleted fiscal years, the alternative quantitative standards for continued listing on the Nasdaq Capital Market. The Letter has no immediate effect on the Company's continued listing on the Nasdaq Capital Market, subject to the Company's compliance with the other continued listing requirements. In accordance with Nasdaq rules, the Company has been provided 45 calendar days, or until July 3, 2023, to submit a plan to regain compliance (theCompliance Plan"). If the Compliance Plan is acceptable to the Staff, they may grant an extension of 180 calendar days from the date of the Staff notification to regain compliance with the Stockholders' EquityRequirement. If the Staff does not accept the Compliance Plan, the Staff will provide written notification to the Company that the Compliance Plan has been rejected. At that time, the Company may appeal the Staff's determination to a Nasdaq Hearings Panel. The Company intends to submit the Compliance Plan on or before July 3, 2023, monitor its stockholders' equity and, if appropriate, consider further available options to regain compliance with the Stockholders' Equity Requirement. There can be no assurance that the Company will be able to regain compliance with the Rule.
Reported Earnings • May 11First quarter 2023 earnings: EPS and revenues miss analyst expectationsFirst quarter 2023 results: US$0.76 loss per share (further deteriorated from US$0.68 loss in 1Q 2022). Net loss: US$3.78m (loss widened 14% from 1Q 2022). Revenue missed analyst estimates by 18%. Earnings per share (EPS) also missed analyst estimates by 20%. Revenue is forecast to grow 64% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 75% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
Recent Insider Transactions • May 11Insider recently bought US$1m worth of stockOn the 5th of May, Jack Schuler bought around 336k shares on-market at roughly US$2.98 per share. This transaction amounted to 53% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$402k more in shares than they have sold in the last 12 months.
お知らせ • May 05Yield10 Bioscience, Inc. to Report Q1, 2023 Results on May 10, 2023Yield10 Bioscience, Inc. announced that they will report Q1, 2023 results on May 10, 2023
Reported Earnings • Mar 16Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: US$2.76 loss per share (further deteriorated from US$2.33 loss in FY 2021). Net loss: US$13.6m (loss widened 23% from FY 2021). Revenue missed analyst estimates by 7.8%. Earnings per share (EPS) also missed analyst estimates by 3.0%. Revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 97% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
Price Target Changed • Jan 19Price target increased to US$14.67Up from US$12.75, the current price target is an average from 3 analysts. New target price is 464% above last closing price of US$2.60. Stock is down 32% over the past year. The company is forecast to post a net loss per share of US$2.68 next year compared to a net loss per share of US$2.33 last year.
Reported Earnings • Nov 17Third quarter 2022 earnings: EPS and revenues miss analyst expectationsThird quarter 2022 results: US$0.71 loss per share (further deteriorated from US$0.49 loss in 3Q 2021). Net loss: US$3.49m (loss widened 46% from 3Q 2021). Revenue missed analyst estimates by 17%. Earnings per share (EPS) also missed analyst estimates by 7.2%. Revenue is forecast to grow 68% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 97% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.
Price Target Changed • Nov 16Price target increased to US$14.67Up from US$12.75, the current price target is an average from 4 analysts. New target price is 449% above last closing price of US$2.67. Stock is down 52% over the past year. The company is forecast to post a net loss per share of US$2.58 next year compared to a net loss per share of US$2.33 last year.
Major Estimate Revision • Aug 17Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$620.0k to US$530.0k. EPS estimate increased from -US$2.72 to -US$2.58 per share. Biotechs industry in the US expected to see average net income decline 57% next year. Consensus price target of US$12.25 unchanged from last update. Share price rose 9.1% to US$2.93 over the past week.
Reported Earnings • Aug 11Second quarter 2022 earnings: EPS and revenues miss analyst expectationsSecond quarter 2022 results: US$0.70 loss per share (down from US$0.64 loss in 2Q 2021). Net loss: US$3.44m (loss widened 11% from 2Q 2021). Revenue missed analyst estimates by 35%. Earnings per share (EPS) also missed analyst estimates by 1.4%. Over the next year, revenue is forecast to grow 310%, compared to a 52% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 94% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings.
Seeking Alpha • Aug 10Yield10 Bioscience GAAP EPS of $0.70 beats by $1.39, revenue of $0.1M misses by $0.06MYield10 Bioscience press release (NASDAQ:YTEN): Q2 GAAP EPS of $0.70 beats by $1.39. Revenue of $0.1M (-41.2% Y/Y) misses by $0.06M.
Major Estimate Revision • May 18Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$970.0k to US$620.0k. EPS estimate increased from -US$2.82 to -US$2.72 per share. Biotechs industry in the US expected to see average net income decline 52% next year. Consensus price target down from US$12.75 to US$12.25. Share price rose 26% to US$2.78 over the past week.
Reported Earnings • May 13First quarter 2022 earnings: EPS and revenues miss analyst expectationsFirst quarter 2022 results: US$0.68 loss per share (down from US$0.60 loss in 1Q 2021). Net loss: US$3.33m (loss widened 30% from 1Q 2021). Revenue missed analyst estimates by 14%. Earnings per share (EPS) also missed analyst estimates by 4.2%. Over the next year, revenue is forecast to grow 481%, compared to a 25% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings.
Price Target Changed • Apr 27Price target decreased to US$15.33Down from US$21.50, the current price target is an average from 3 analysts. New target price is 367% above last closing price of US$3.28. Stock is down 68% over the past year. The company is forecast to post a net loss per share of US$2.67 next year compared to a net loss per share of US$2.33 last year.
Price Target Changed • Mar 11Price target decreased to US$17.00Down from US$24.50, the current price target is an average from 2 analysts. New target price is 215% above last closing price of US$5.40. Stock is down 60% over the past year. The company is forecast to post a net loss per share of US$2.50 next year compared to a net loss per share of US$2.33 last year.
分析記事 • Nov 12Is Yield10 Bioscience (NASDAQ:YTEN) In A Good Position To Invest In Growth?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Reported Earnings • Nov 12Third quarter 2021 earnings released: US$0.49 loss per share (vs US$0.87 loss in 3Q 2020)Third quarter 2021 results: Net loss: US$2.40m (loss widened 11% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 78% per year but the company’s share price has fallen by 53% per year, which means it is significantly lagging earnings.
Major Estimate Revision • Aug 18Consensus revenue estimates fall to US$890.0kThe consensus outlook for revenues in 2021 has deteriorated. 2021 revenue forecast decreased from US$1.08m to US$890.0k. Forecast losses increased from -US$2.23 to -US$2.58 per share. Biotechs industry in the US expected to see average net income decline 21% next year. Consensus price target down from US$24.50 to US$21.50. Share price fell 18% to US$5.84 over the past week.
Price Target Changed • Aug 13Price target decreased to US$21.50Down from US$24.50, the current price target is an average from 2 analysts. New target price is 225% above last closing price of US$6.61. Stock is up 22% over the past year.
Reported Earnings • Aug 13Second quarter 2021 earnings released: US$0.64 loss per share (vs US$0.92 loss in 2Q 2020)Second quarter 2021 results: Net loss: US$3.09m (loss widened 72% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 74% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings.
分析記事 • Jul 19Yield10 Bioscience (NASDAQ:YTEN) Is In A Good Position To Deliver On Growth PlansWe can readily understand why investors are attracted to unprofitable companies. For example, although...
分析記事 • May 18Yield10 Bioscience, Inc.'s (NASDAQ:YTEN) CEO Will Probably Find It Hard To See A Huge Raise This YearThe underwhelming share price performance of Yield10 Bioscience, Inc. ( NASDAQ:YTEN ) in the past three years would...
Major Estimate Revision • May 18Consensus revenue estimates fall to US$1.08mThe consensus outlook for revenues in 2021 has deteriorated. 2021 revenue forecast decreased from US$1.41m to US$1.08m. Forecast losses increased from -US$2.06 to -US$2.23 per share. Biotechs industry in the US expected to see average net income decline 8.7% next year. Consensus price target of US$24.50 unchanged from last update. Share price fell 22% to US$7.50 over the past week.
Reported Earnings • May 14First quarter 2021 earnings released: US$0.60 loss per share (vs US$2.12 loss in 1Q 2020)First quarter 2021 results: Net loss: US$2.56m (loss narrowed 29% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 74% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings.
分析記事 • Apr 14Here's Why We're Watching Yield10 Bioscience's (NASDAQ:YTEN) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, Yield10 Bioscience...
Major Estimate Revision • Mar 23Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast fell from US$1.47m to US$1.29m. EPS estimate increased from -US$2.32 to -US$2.06 per share. Biotechs industry in the US expected to see average net income growth of 4.2% next year. Consensus price target of US$25.33 unchanged from last update. Share price fell 3.1% to US$15.56 over the past week.
Reported Earnings • Mar 20Full year 2020 earnings released: US$4.30 loss per share (vs US$35.50 loss in FY 2019)Full year 2020 results: Net loss: US$10.2m (loss narrowed 21% from FY 2019). Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Feb 09New 90-day high: US$18.86The company is up 213% from its price of US$6.03 on 10 November 2020. The American market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 25% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$27.40 per share.
分析記事 • Jan 22When Will Yield10 Bioscience, Inc. (NASDAQ:YTEN) Become Profitable?We feel now is a pretty good time to analyse Yield10 Bioscience, Inc.'s ( NASDAQ:YTEN ) business as it appears the...